Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study

Figures & data

Table 1 Demographic and Basal Characteristics of the Studied Cohort

Variable	Overall n=49
Sex, women, n (%)	27 [55.1]
Age (years), mean [Range]	60.82 [35 a 80]
Body weight (kg), mean [SD]	84.22 [15.10]
Glycosylated hemoglobin (%), mean [SD]	10.13 [2.53]
Fasting glycemia (mg/dL), median [Range]	200.15 [72.2 a 468]
Albumin-to-creatinine ratio (mg/g), median [Range]	37.58 [0.52 a 1765.22]

Note: n=Sample size.

Abbreviations: HbA1C, Glycosylated hemoglobin; SD, Standard deviation.

Figure 1 Glycosylated hemoglobin at baseline and 3-, 6-, and 12-months follow-up.

Note: n=Sample size.

Abbreviation: HbA1C, Glycosylated hemoglobin (5).

Figure 2 Baseline body weight and at follow-up at 3, 6 and 12 months.

Notes: Weight is expressed in kilograms, n=Sample size.

Table 2 ACR Index Classification Baseline and During the Follow-Up

Follow-Up Month (n)	Basal (n=49)	3 Months (n=49)	6 Months (n=47)	12 Months (n=38)
ACR <30 n (%)	20 (40.8)	29 (59.2)	29 (61.7)	24 (63.2)
ACR 30–300 n (%)	23 (46.9)	18 (36.7)	16 (34)	12 (31.6)
ACR >300 n (%)	6 (12.2)	2 (4.1)	2 (4.3)	2 (5.3)
P* value		0.025	0.003	0.112

Notes: n=Sample size, *Mc Neamar test.

Abbreviation: ACR, Albumin/creatinine ratio.

Table 3 Adverse Reactions Presented During the Study Time

Variables	Overall
Adverse events, n (%)	8 [16.3]
Adverse events leading to discontinuation of treatment, n (%)	4 [8.2]
Description of adverse events*
Diarrhea, n (%)	2 [4.1]
Emesis, n (%)	3 [6.1]
Severe constipation, n (%)	2 [4.1]
Severe hypoglycemia, n (%)	2 [4.1]
Biliary Pancreatitis, n (%)	1 [2.0]

Notes: n=Sample size, *Non-exclusive categories.